Johnson & Johnson Receives Canadian Approval for Rybrevant in First-line NSCLC

Seeking Alpha03:21

U.S. Indicated Dividend Payments Rose in Q2 Led by Alphabet's Initiation

Indicated dividend net changes for U.S. domestic common stocks rose $16.05B in Q2, as compared to a $16.03B increase in the prior quarter, according to the data from S&P Dow Jones Indices.

Seeking AlphaJul 3 23:06

Top High Quality Stocks That Pay Dividends - UBS

Seeking AlphaJul 3 22:23

Johnson & Johnson Lung Cancer Drug Gets Health Canada Approval

By Michael Susin Johnson & Johnson said the Canadian health authority issued a notice of compliance for its lung-cancer treatment, meaning the drug is authorized to be marketed under certain conditio

WSJJul 3 20:28

Express News | Health Canada Authorizes Rybrevant® (Amivantamab) in Combination With Carboplatin and Pemetrexed as the Only Targeted First-Line Treatment Approved for Patients With Non-Small Cell Lung Cancer With Egfr Exon 20 Insertion Mutations

BreakingsJul 3 20:00

Johnson & Johnson (JNJ.US) / Legend Biotech (LEGN.US) CAR-T therapy has achieved positive results in phase III.

According to the news from the Securities Times app, on July 3, Johnson & Johnson (JNJ.US) and Legend Biotech (LEGN.US) jointly announced the positive results of the planned second interim analysis of the Phase 3 CARTITUDE-4 study. The study evaluated the chimeric antigen receptor (CAR) T cell therapy Carvykti jointly developed by the two companies, compared to standard therapy, for the treatment of patients with relapsed or refractory multiple myeloma (MM) who are resistant to lenalidomide after 1st-line treatment. The interim analysis showed that compared with standard therapy, patients treated with Carvykti had a longer overall survival.

Zhitong FinanceJul 3 10:03